Emergent BioSolutions
EBS
C$9.66
Share price
7.73%
Change (1 day)
-5.41%
Change (1 year)
Categories
Emergent BioSolutions (EBS) - Total liabilities
Total liabilities on the balance sheet as of March 2025 : C$1.18 Billion
According to Emergent BioSolutions 's latest financial reports the company's total liabilities are C$1.18 Billion. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Emergent BioSolutions - Total liabilities on balance sheet (from 2004 to 2025)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2024-12-31 | C$1.30 B | -16.42% |
| 2023-12-31 | C$1.55 B | -35.49% |
| 2022-12-31 | C$2.41 B | 40.67% |
| 2021-12-31 | C$1.71 B | -6.31% |
| 2020-12-31 | C$1.83 B | 13.18% |
| 2019-12-31 | C$1.61 B | -2.52% |
| 2018-12-31 | C$1.65 B | 736.11% |
| 2017-12-31 | C$0.19 B | -60.49% |
| 2016-12-31 | C$0.50 B | -4.04% |
| 2015-12-31 | C$0.52 B | 17.05% |
| 2014-12-31 | C$0.44 B | 205.71% |
| 2013-12-31 | C$0.14 B | 20.52% |
| 2012-12-31 | C$0.12 B | -8.28% |
| 2011-12-31 | C$0.13 B | 4.47% |
| 2010-12-31 | C$0.12 B | 19.38% |
| 2009-12-31 | C$0.10 B | -4.53% |
| 2008-12-31 | C$0.11 B | 8.89% |
| 2007-12-31 | C$0.10 B | -12.11% |
| 2006-12-31 | C$0.11 B | 145.81% |
| 2005-12-31 | C$47.26 M | -14.66% |
| 2004-12-31 | C$55.37 M | |
| 2002-12-31 | C$29.43 M | -67.99% |
| 2001-12-31 | C$91.94 M |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Merck MRK | C$90.63 B | 7,539.34% | 🇺🇸 USA |
 SIGA Technologies SIGA | C$42.02 M | -96.46% | 🇺🇸 USA |
 GlaxoSmithKline GSK | C$82.58 B | 6,860.63% | 🇬🇧 UK |
 Celldex Therapeutics CLDX | C$49.57 M | -95.82% | 🇺🇸 USA |
 Pfizer PFE | C$159.47 B | 13,340.69% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | C$43.66 B | 3,580.56% | 🇮🇱 Israel |
 Soligenix SNGX | C$5.61 M | -99.53% | 🇺🇸 USA |